TIAA CREF Investment Management LLC raised its position in Opko Health, Inc. (NASDAQ:OPK) by 4.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,016,286 shares of the biotechnology company’s stock after purchasing an additional 44,156 shares during the quarter. TIAA CREF Investment Management LLC owned 0.18% of Opko Health worth $6,687,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Financial Architects Inc raised its stake in shares of Opko Health by 45.0% in the 2nd quarter. Financial Architects Inc now owns 15,460 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 4,800 shares during the period. Blair William & Co. IL acquired a new stake in shares of Opko Health in the 2nd quarter valued at about $112,000. Engineers Gate Manager LP acquired a new stake in shares of Opko Health in the 2nd quarter valued at about $117,000. IFC Holdings Incorporated FL raised its stake in shares of Opko Health by 16.5% in the 2nd quarter. IFC Holdings Incorporated FL now owns 17,864 shares of the biotechnology company’s stock valued at $119,000 after purchasing an additional 2,525 shares during the period. Finally, Envestnet Asset Management Inc. raised its stake in shares of Opko Health by 6.5% in the 1st quarter. Envestnet Asset Management Inc. now owns 16,356 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 1,001 shares during the period. 22.46% of the stock is currently owned by hedge funds and other institutional investors.
OPK has been the topic of several recent research reports. BidaskClub raised Opko Health from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $19.50 target price on shares of Opko Health in a research report on Friday, June 16th. Zacks Investment Research downgraded Opko Health from a “buy” rating to a “hold” rating in a research report on Saturday, August 12th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $6.50 target price (down previously from $6.80) on shares of Opko Health in a research report on Thursday, August 10th. Finally, J P Morgan Chase & Co downgraded Opko Health from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $12.00 to $7.00 in a research report on Thursday, September 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $13.97.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/10/13/tiaa-cref-investment-management-llc-purchases-44156-shares-of-opko-health-inc-opk.html.
Shares of Opko Health, Inc. (NASDAQ:OPK) opened at 6.88 on Friday. The stock’s 50 day moving average price is $6.53 and its 200-day moving average price is $6.73. The company’s market cap is $3.85 billion. Opko Health, Inc. has a one year low of $5.85 and a one year high of $12.15.
Opko Health (NASDAQ:OPK) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The company had revenue of $314.20 million during the quarter, compared to analyst estimates of $322.64 million. During the same quarter last year, the business posted $0.02 EPS. Opko Health’s quarterly revenue was down 12.0% compared to the same quarter last year. On average, analysts expect that Opko Health, Inc. will post ($0.20) EPS for the current year.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
What are top analysts saying about Opko Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Opko Health Inc. and related companies.